RecruitingPhase 2NCT05930665

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Studying Pleural mesothelioma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sun Yat-sen University
Intervention
Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin(drug)
Enrollment
38 enrolled
Eligibility
18 years · All sexes
Timeline
2023 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05930665 on ClinicalTrials.gov

Other trials for Pleural mesothelioma

Additional recruiting or active studies for the same condition.

See all trials for Pleural mesothelioma →

← Back to all trials